Mira Precision Health today announced the official U.S. launch of ToxNav^® Advantage^™, a clinically validated pharmacogenomic assay designed to identify cancer patients at increased risk of severe or potentially life-threatening toxicities from fluoropyrimidine-based chemotherapies, including 5-fluorouracil (5-FU) and capecitabine (XELODA^®).